Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

By Zhu Yuanxi  

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1349-1362

Springer Publishing Company

Access to resources Recommend Favorite

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

By Macaskill E.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 725-734

Springer Publishing Company

Access to resources Recommend Favorite

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

By Sabine Vicky  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 419-428

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 471-477

Spandidos Publications

Access to resources Recommend Favorite